Ovarian and Prostate Cancer (PARPi) [Tissue, Somatic]
BRCA1, BRCA2 and HRR testing for Ovarian and Prostate cancer in the context of PARP inhibitor prescription (FFPE). This EQA is sponsored.
NGS for somatic SNVs and indels – tumour with germline subtraction analysis
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.
NGS for somatic SNVs and indels – tumour testing only
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS NOT requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.
Urothelial/bladder cancer (FGFR SNV/fusions) [Tissue]
FGFR3 testing (SNVs and gene fusions) in Urothelial / Bladder cancer (FFPE)
Pan-Tumour Fusions [FFPE]
Fusion gene testing for fusions relevant to therapy (ALK, ROS1, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, or FGFR3) for solid cancers (FFPE)
Homologous Recombination Deficiency (HRD) testing in ovarian cancer [Tissue]
HRD testing for Ovarian Cancer (Tissue). This EQA is sponsored.